[Efficacy, safety and indication of newly developed insulin analogs].
A newly developed fast-acting analogs of human insulin can attain more physiological plasma profiles than those of regular human insulin. These pharmacokinetic plasma profiles have greater merits than those of regular human insulin. These pharmacokinetic properties allow for good glycemic control especially after meal with subsequent reduction of HbA1c levels during intensive insulin therapy. Furthermore, the frequencies of hypoglycemia are reduced by using fast-acting human insulin analogs. Long-term uses of these analogs do not have adverse effects including carcinogenesis and do not enhance the growth of vascular smooth muscle tissue. These analogs do not cause insulin allergy. A few reports describe beneficial effect on lipoatrophy of the subcutaneous tissues induced by human regular insulin treatment. Fast-absorbing and fast-acting insulin analog will be suitable for the treatment of type 1 diabetic patients with continuous subcutaneous insulin infusion(CSII).
Kobayashi
T
T
Department of Endocrinology and Metabolism, Toranomon Hospital.
D000595:Amino Acid Sequence; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D061267:Insulin Aspart; D007332:Insulin Infusion Systems; D061268:Insulin Lispro; D008969:Molecular Sequence Data; D019518:Postprandial Period
D001786:Blood Glucose; D007328:Insulin; D061268:Insulin Lispro; D061267:Insulin Aspart